Emerging drugs for the treatment of benign prostatic hyperplasia

References

• Hong SJ, Rayford W, Valiquette L, et al. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int. 2005 Jan;95(1):15–19.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Forde JC, Thomas DD, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
   PubMed Web of Science ®Google Scholar
• Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology. 1998 Apr;51(4ASuppl):8–12.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Campbell-Walsh Urol. 2005;7:S3–s14.
   Google Scholar
• Park HJ, Won JEJ, Sorsaburu S, et al. Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013 Dec;31(3):193–207.
   PubMedGoogle Scholar
• Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol. 2005;7(Suppl 4):S3–S12.
   Google Scholar
• Tubaro A, La Vecchia C. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur Urol. 2004 Jun;45(6):767–772.
   PubMed Web of Science ®Google Scholar
• Mitropoulos D, Anastasiou I, Giannopoulou C, et al. Symptomatic benign prostate hyperplasia: impact on partners’ quality of life. Eur Urol. 2002 Mar;41(3):240-244;discussion 244–245.
   PubMed Web of Science ®Google Scholar
• Sells H, Donovan J, Ewings P, et al. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int. 2000 Mar;85(4):440–445.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Aronson W, Freedland S, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560–570.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B, Holthuis N, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–162.
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015 Jan;115(1):24–31.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Smit E, Giovannucci E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the third National Health and Nutrition Examination Survey (NHANES III). Int J Obes. 2005;29(3):310–316.
   PubMed Web of Science ®Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006 Aug;370(1–2):89–93.
   PubMed Web of Science ®Google Scholar
• Gacci M, Sebastianelli A, Salvi M, et al. Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017;17:1–6.
   Web of Science ®Google Scholar
• EAU. Guidelines on the management of non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)). 2015.
   Google Scholar
• Foglar R, Shibata K, Horie K, et al. Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201–207.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015 Jun;67(6):1099–1109.
   PubMed Web of Science ®Google Scholar
• Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009 Jun;181(6):2634–2640.
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Mizuno T, Tatsumiya K, et al. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010 Apr;29(4):558–562.
   PubMed Web of Science ®Google Scholar
• Michel MC. α(1)-Adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152(3):289–290. 07/02 05/01/received 06/05/accepted.
   PubMed Web of Science ®Google Scholar
• Zhu YS, Sun GH. 5α-reductase isozymes in the prostate. J Med Sci. 2005;25(1):1–12.
   PubMedGoogle Scholar
• O’Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measure in patients with enlarged prostate (PDF Download Available). 2008.Prostate Cancer and Prostatic Diseases/ Nature Publishing group. Available from: https://www.nature.com/pcan/journal/v11/n2/pdf/4500990a.pdf?origin=publication_detail&foxtrotcallback=true
   Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998 Feb 26;338(9):557–563.
   PubMed Web of Science ®Google Scholar
• Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol. 1995;27(4):267–273.
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004 Oct;46(4):488-494; discussion 495.
   Web of Science ®Google Scholar
• Regadas RP, Reges R, Cerqueira JB, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol. 2013 Feb;45(1):39–43.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003 Jul;44(1):82–88.
   PubMed Web of Science ®Google Scholar
• Giuliano F, Uckert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013 Mar;63(3):506–516.
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012 May;61(5):917–925.
   PubMed Web of Science ®Google Scholar
• Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009 Oct;56(4):727–735.
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012 May;61(5):994–1003.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123–131.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013 Sep;73(13):1391–1402.
   PubMed Web of Science ®Google Scholar
• Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol. 2014 Jan;24(1):21–28.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013 Feb;63(2):283–295.
   PubMed Web of Science ®Google Scholar
• Sacco E, Mirabegron: BR. a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012 Dec;4(6):315–324.
   PubMedGoogle Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013 Oct;190(4):1320–1327.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–2398.
   PubMed Web of Science ®Google Scholar
• Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis. 2009;12(4):369–374.
   PubMed Web of Science ®Google Scholar
• Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009 Apr;103(7):919–926.
   PubMed Web of Science ®Google Scholar
• Jeong YB, Kwon KS, Kim SD, et al. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology. 2009 Apr;73(4):802–806.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2319–2328.
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003 Jun;169(6):2253–2256.
   PubMed Web of Science ®Google Scholar
• Kaplan S, Gonzalez R, Te A. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717–1723.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008 Oct;180(4):1228–1234.
   PubMed Web of Science ®Google Scholar
• Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008 Jun;53(6):1236–1244.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010 Mar;183(3):1092–1097.
   PubMed Web of Science ®Google Scholar
• Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010 Feb;28(1):17–22.
   PubMed Web of Science ®Google Scholar
• Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2014 Mar;193(3):921–926.
   PubMed Web of Science ®Google Scholar
• Chung DE, Te AE, Staskin DR, et al. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010 May;75(5):1144–1148.
   PubMed Web of Science ®Google Scholar
• Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2013 Mar;191(3):727–733.
   PubMed Web of Science ®Google Scholar
• Stroup SP, Palazzi-Churas K, Kopp RP, et al. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU International. 2011 Jan;109(1):84–87.
   PubMed Web of Science ®Google Scholar
• Groves HK, Chang D, Palazzi K, et al. The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis. 2013 Sep;16(3):260–265.
   PubMed Web of Science ®Google Scholar
• Dahm P, Brasure M, MacDonald R, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2016 Apr;71(4):570–581.
   PubMed Web of Science ®Google Scholar
• Gburcik V. BPH Treatment Market Value to reach Nearly $5B by 2024. Drug Discovery and Development. 2015. Available from: https://www.dddmag.com/news/2015/09/bph-treatment-market-value-reach-nearly-5b-2024
   Google Scholar
• DeLay KJ, Kohler TS. Testosterone and the prostate: artifacts and truths. Urol Clin North Am. 2016 Aug;43(3):405–412.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20(Suppl 3):S11–S18.
   PubMed Web of Science ®Google Scholar
• Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol. 1997;32(Suppl 3):24–40.
   PubMed Web of Science ®Google Scholar
• Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003 Apr;61(4 Suppl 1):2–7.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Briganti A, Suardi N, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011 Aug;52(8):507–516.
   PubMedGoogle Scholar
• Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009 Dec 01;69(16):1774–1780.
   PubMed Web of Science ®Google Scholar
• Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2009 Jun 1;33(3):475–488.
   PubMedGoogle Scholar
• Chughtai B, Lee R, Te A, et al. Inflammation and benign prostatic hyperplasia: clinical implications. Curr Urol Rep. 2011;12(4):274–277.
   PubMedGoogle Scholar
• Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004 Sep 15;61(1):60–72.
   PubMed Web of Science ®Google Scholar
• Maserejian NN, Giovannucci EL, McVary KT, et al. Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men12. J Nutr. 2011;141:267–273.
   PubMed Web of Science ®Google Scholar
• Kathleen H, Portland OR, Parsons JK, et al. 1736 higher dietary intakes of vitamin c and some carotenoids are associated with reduced progression of lower urinary tract symptoms in elderly men: the mros study. J Urol. 2013 Apr 1;189(4):e713.
   Web of Science ®Google Scholar
• Halmos G, Arencibia JM, Schally AV, et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol. 2000 Feb;163(2):623–629.
   PubMed Web of Science ®Google Scholar
• Comaru-Schally AM. [GnRH antagonists and prostatic hyperplasia]. Rev Prat. 2005. Spec. No:28-29. 39:S73–77.
   PubMedGoogle Scholar
• Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2008 Jul;54(1):170–177.
   PubMed Web of Science ®Google Scholar
• Calisha Myers. AEterna zentaris announces results from two phase 3 studies with cetrorelix in benign prostatic hyperplasia |fierceBiotech. 2009. Available from: http://www.fiercebiotech.com/biotech/aeterna-zentaris-announces-results-from-two-phase-3-studies-cetrorelix-benign-prostatic
   Google Scholar
• Daniel Croteau. AEterna Zantaris. Cetrorelix pamoate IM regimens in patients with symptomatic Benign Prostatic Hyperplasia (BPH) - study results - ClinicalTrials.gov. 2011. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00670306
   Google Scholar
• Festuccia c, Dondi D, Piccolella M, et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep;70(12):1340–1349. doi: 10.1002/pros.21169.
   Google Scholar
• Debruyne F. MP-20.02: the efficacy, duration of efficacy and safety of Ozarelix, a novel GnRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) - ScienceDirect. Urology. 2007 Sept;70(3):149–150.
   Google Scholar
• Nikolovski CM, Larsen F, Drewe J, et al. 346 efficacy and safety of teverelix La, a new GnRH antagonist in patients with Benign Prostatic Hyperplasia (BPH). Results from a phase ii randomized, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections Of 60 mg at 48 hours interval administered s.c. to treatment naïve patients suffering from BPH. Eur Urol Supplements. 2007 Mar 1;6(2):109.
   Web of Science ®Google Scholar
• BioSpace. Neurocrine biosciences inc s elagolix successful in six month lilac petal study safety and efficacy confirmed in patients with endometriosis. 2009. Available from: https://www.biospace.com/News/neurocrine-biosciences-inc-s-elagolix-successful/151474/source=TopBreaking
   Google Scholar
• Kahokehr A, Vather R, Nixon A, et al. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU International. 2013 Feb;111(2):304–311.
   PubMed Web of Science ®Google Scholar
• Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001 Sep;54(9):935–944.
   PubMed Web of Science ®Google Scholar
• Kang D, Gl A, Rc VDV, et al. Risk behaviours and benign prostatic hyperplasia. BJU International. 2004 Jun;93(9):1241–1245.
   PubMed Web of Science ®Google Scholar
• Schenk JM, Calip GS, Tangen CM, et al. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012;176:156–163.
   PubMed Web of Science ®Google Scholar
• Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011;2:377–383.
   PubMedGoogle Scholar
• Chughtai B, Dunphy C, Lee R, et al. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014 Apr;21(2):7217–7221.
   PubMed Web of Science ®Google Scholar
• Marberger M, Chartier-Kastler E, Egerdie B, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2012 Oct 12;63(3):496–503.
   Google Scholar
• Allergan. A study evaluating the effect of botulinum toxin type A on semen quality in patients with benign prostatic hyperplasia - Study Results - ClinicalTrials.gov. 2013. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00894517
   Google Scholar
• Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011 Sep;186(3):965–970. doi: 10.1016/j.juro.2011.04.062. Epub 2011 Jul 24.
   Google Scholar
• Avins AL, Lee JY, Meyers CM, et al. Safety and toxicity of saw palmetto in the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) trial. J Urol. 2012 Oct 9;189(4):1415–1420.
   PubMed Web of Science ®Google Scholar
• Ausio Pharmaceuticals LLC. Efficacy and safety of S-Equol on men with benign prostatic hyperplasia - Study Results - ClinicalTrials.gov. 2017. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00962390
   Google Scholar
• Wong WC, Wong EL, Li H, et al. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Complementary Med (New York, NY). 2012 Jan;18(1):54–60.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Takeda M, Hosaka M, et al. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]. Hinyokika Kiyo. Acta Urologica Japonica. 2002 May;48(5):269–273.
   PubMedGoogle Scholar
• Fujimoto K, Hirao Y, Masumori N, et al. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study. Int J Urol. 2006 May;13(5):543–549.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Hirao Y, Ohashi Y, et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol. 2013;2013:1–8.
   Google Scholar
• Ruijter E, Van DVMK. Use of etonogestrel for benign prostate hyperplasia (bph). Google Patents; 2009. Available from: https://www.google.com/patents/WO2009101182A1?cl=en
   Google Scholar
• Denmeade SR, Egerdie B, Steinhoff G, et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2010 May;59(5):747–754.
   PubMed Web of Science ®Google Scholar
• Sophiris. Overview: clinical Trials; 2015 Jan 27. 2016. Available from: http://www.sophirisbio.com/clinical_trials/
   Google Scholar
• Corp SB. Transperineal intraprostatic injection of PRX302 under ultrasound guidance for management of prostatic hyperplasia - Study Results - ClinicalTrials.gov. Sophiris Bio Corp. 2013. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00889707
   Google Scholar
• Corp SB. Study of PRX302 for lower urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH) - Full Text View - ClinicalTrials.gov. Sophiris Bio Corp. 2013. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01454349
   Google Scholar
• Wang S, Bromley E, Xu L, et al. Talaporfin sodium. Expert Opin Pharmacother. 2009 Jan;11(1):133–140.
   Web of Science ®Google Scholar
• Penna G, Fibbi B, Amuchastegui S, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2008 Apr 01;69(5):480–493.
   Web of Science ®Google Scholar
• Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2005 Jan;49(1):82–86.
   PubMed Web of Science ®Google Scholar
• Colli FM. Enrico. Elocalcitol in the treatment of BPH: a multicenter, randomized, placebo-controlled phase IIB clinical trial. J Urol. 2008 Apr 1;179(4): 700–701.
   Web of Science ®Google Scholar
• Rosette SG, Jean JDL. Investigational therapies targeted to the treatment of benign prostatic hyperplasia. 2013 Feb 11. DOI:10.1517/13543784.2013.761973
   Google Scholar
• Rees RW, Foxwell NA, Ralph DJ, et al. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003 Dec;170(6 Pt 1):2517–2522.
   PubMed Web of Science ®Google Scholar
• Wennemuth G, Aumuller G. Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br J Pharmacol. 2005 Jan;144(1):3–10.
   PubMed Web of Science ®Google Scholar